Key Highlights

  • Kyntra Bio (NASDAQ:KYNB) reported third-quarter 2026 Net Income of USD 0.2 million, or USD 0.04 per share, against a net income of USD 200.6 million a year earlier that came from discontinued operations.
  • A USD 14.0 million net gain on restructuring a Revenue interest financing agreement offset a USD 12.9 million loss from operations.
  • Total revenue rose 64% to USD 1.8 million, while Research and Development expense climbed to USD 8.3 million from USD 1.2 million.
  • Cash, investments and receivables totaled USD 44.1 million at September 30, 2026, down USD 65.2 million from year-end 2025.

Restructuring Gain Turns the Quarter Positive

Kyntra Bio (NASDAQ:KYNB), the former FibroGen, is a rare disease drug developer focused on roxadustat for anemia in lower-risk myelodysplastic syndromes. The company rebranded in January 2026 and its shares began trading under the new symbol on January 8, 2026. Its quarterly filing dated November 16, 2026 shows income from continuing operations of USD 0.2 million, compared with a loss of USD 13.1 million in the same quarter a year earlier. The swing came from a USD 14.0 million net gain on Debt restructuring, recorded after the company amended its revenue interest financing agreement with NovaQuest on August 31, 2026. The loss from operations widened to USD 12.9 million from USD 5.4 million.

NovaQuest Deal Cuts the Cap but Drains Cash

The amended agreement lowered maximum aggregate payments from USD 125.0 million to USD 65.0 million. Kyntra Bio made an upfront payment of USD 42.6 million, taking total payments to USD 50.0 million and leaving a remaining cap of USD 15.0 million. From here the company pays 50% of the revenue it is entitled to under its Astellas Europe agreements, and Japan royalties are released from the arrangement. Cash, investments and receivables totaled USD 44.1 million, and the filing says current cash is sufficient to fund planned operating requirements for at least twelve months. Operating Activities used USD 30.1 million of cash over nine months.

Higher Research Spending as FG-3246 Is Dropped

Research and development expense reached USD 8.3 million in the quarter against USD 1.2 million a year earlier, and USD 22.7 million over nine months. Selling, general and administrative expense was USD 5.8 million. In the fourth quarter the company stopped development of FG-3246 in metastatic castration-resistant prostate cancer, citing insufficient efficacy, and will end its Fortis license and Acquisition option. It will not pay the option exercise or contingent payments. For roxadustat, the Phase 3 protocol is final, and the company aims to start the trial in the first quarter of 2027, subject to a strategic Partnership or an external Capital raise. Nine-month revenue fell 22% to USD 4.0 million, and a USD 30.9 million gain from deconsolidating FibroGen Europe helped hold the nine-month loss from continuing operations to USD 3.0 million.

Where Things Stand

Yes, mostly. Kyntra Bio (NASDAQ:KYNB) earned USD 0.2 million because of a USD 14.0 million debt restructuring gain, while the underlying operations lost USD 12.9 million. Cash, investments and receivables of USD 44.1 million are said to cover twelve months, but the Phase 3 start depends on a partner or new capital. A separate matter is listing status: Nasdaq staff determined in September 2026 that the company did not meet a total Assets and revenue requirement for the Global Select Market, a hearing took place on November 5, 2026, and the panel decision is pending. Watch the panel ruling and any partnership news.